Zubkiewicz-Kucharska Agnieszka, Jamer Tatiana, Chrzanowska Joanna, Akutko Katarzyna, Pytrus Tomasz, Stawarski Andrzej, Noczyńska Anna
Department of Pediatric Endocrinology and Diabetology for Children and Adolescents, Wroclaw Medical University, Wroclaw, Poland.
Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Wroclaw, Poland.
Diabetol Metab Syndr. 2022 Sep 12;14(1):128. doi: 10.1186/s13098-022-00897-8.
Type 1 diabetes (T1D) and celiac disease (CD) coexist very often. Identification of the human leukocyte antigen (HLA) DQ2/DQ8 can confirm the genetic predisposition to CD. Negative result of this test allows to exclude CD with a high probability. It was suggested that in individuals with higher risk of CD, including T1D patients, the implementation of genetic testing should reduce the number of patients requiring systematic immunological screening. The aim of this study was to analyze the prevalence of different haplotypes predisposing to CD in children and adolescents with previously diagnosed T1D.
A retrospective analysis was performed on 166 T1D children (91 girls) in whom HLA DQ2/DQ8 alleles were tested. In 9.6% CD was also diagnosed.
In 12.7% both HLA DQ2/DQ8 were negative. In 87.3% patients HLA DQ2 and/or DQ8 was positive, including 27.7% patients with both haplotypes DQ2.5 and DQ8 positive. In all CD patients the disease predisposing alleles were positive, while none of the HLA DQ2/DQ8 negative children were diagnosed with CD.
The prevalence of HLA DQ2.5 and the HLA DQ2.5 / HLA DQ8 configuration is higher in patients with T1D, and CD compared to children with T1D alone. The combination of HLA DQ2 and HLA DQ8 most significantly increases the risk of developing CD. The group of HLA DQ2/DQ8 negative patients with improbable CD diagnosis, is relatively small. Most of T1D patients HLA DQ2/DQ8 positive need further regular antibody assessment. In patients with T1D, who are at high risk of developing CD, genetic testing may be considered to select those who require further systematic serological evaluation. Due to its retrospective nature, the study was not registered in the database of clinical trials and the Clinical trial registration number is not available.
1型糖尿病(T1D)和乳糜泻(CD)常常共存。人类白细胞抗原(HLA)DQ2/DQ8的鉴定可以确认患CD的遗传易感性。该检测结果为阴性则很有可能排除CD。有人提出,在患CD风险较高的个体中,包括T1D患者,进行基因检测应能减少需要进行系统免疫筛查的患者数量。本研究的目的是分析先前诊断为T1D的儿童和青少年中易患CD的不同单倍型的患病率。
对166名检测了HLA DQ2/DQ8等位基因的T1D儿童(91名女孩)进行了回顾性分析。其中9.6%的儿童也被诊断出患有CD。
12.7%的患者HLA DQ2/DQ8均为阴性。87.3%的患者HLA DQ2和/或DQ8为阳性,其中27.7%的患者单倍型DQ2.5和DQ8均为阳性。所有CD患者中,疾病易感等位基因均为阳性,而HLA DQ2/DQ8阴性的儿童均未被诊断出患有CD。
与仅患T1D的儿童相比,T1D合并CD患者中HLA DQ2.5以及HLA DQ2.5/HLA DQ8组合的患病率更高。HLA DQ2和HLA DQ8的组合最显著增加患CD的风险。HLA DQ2/DQ8阴性且CD诊断可能性不大的患者群体相对较小。大多数HLA DQ2/DQ8阳性的T1D患者需要进一步定期进行抗体评估。对于有高风险患CD的T1D患者,可考虑进行基因检测以筛选出那些需要进一步系统血清学评估的患者。由于本研究具有回顾性,未在临床试验数据库中注册,因此没有临床试验注册号。